Clinical trial · Observational
The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer
Neoadjuvant Chemotherapy Versus Surgery Alone in Locally Advanced Gastric Cancer: A Randomized Controlled Study
NCT01444755CI-TRIAL-00005574unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate survival benefit of a neoadjuvant chemotherapy regimen in patient with resectable locally advanced gastric cancer in comparison with surgery alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- 1-Neoadjuvant Chemotherapy
- description
- This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
- label
- 2 Surgery
- description
- Surgery will be performed in patients of this arm.
Primary outcomes (1)
- measure
- Survival
- timeFrame
- After 2 years from therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven adenocarcinoma of stomach * T3 or T4 * N1 or N2 * M0 * No evidence of para-aortic or retropancreatic lymph node metastasis, peritoneal dissemination or Krukenberg tumor. * No involvement of the esophagus with \> 2cm * An age of 18-90 years * A Karnofsky Performance status with 60-100% or Eastern Cooperative Oncology Group (ECOG) performance status (0-2) * No previous chemotherapy, radiotherapy for any malignancy. * No previous surgery for gastric cancer * No evidence obstructive or bleeding symptoms. * Adequate renal and hepatic function * Written informed consent Exclusion Criteria: * Synchronous or metachronous malignancy diagnosing within 5 year * Pregnancy or lactation in female patients * Any immunosuppressive condition (acquired or iatrogenic) * Any infectious toxic or mental condition preventing neoadjuvant therapy
References
Publications (0)
Data not yet available
No reference posted for this study.